Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Covington
US Department of Justice
QuintilesIMS
Queensland Health
Colorcon
Healthtrust
Julphar
McKinsey

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Substituted aromatic sulfonamides as antiglaucoma agents
Abstract:Aromatic sulfonamides with a saturated heterocycle fused thereto are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.
Inventor(s): Ponticello; Gerald S. (Lansdale, PA), Wiggins; J. Mark (Perkasie, PA)
Assignee: Merck & Co., Inc. (Rayway, NJ)
Filing Date:Jun 26, 1987
Application Number:07/067,332
Claims:1. A process for the preparation of a compound of structural formula: ##STR28## wherein R.sup.14 is

(a) hydrogen,

(b) --CN,

(c) phenyl--C.sub.1-3 alkyl, wherein the phenyl is either unsubstituted or substituted with one or more of

(1) hydroxy,

(2) C.sub.1-3 alkoxy,

(3) R.sup.17 R.sup.18 N--C.sub.1-5 alkyl, wherein R.sup.17 and R.sup.18 are independently selected from:

(i) hydrogen or

(ii) C.sub.1-3 alkyl, or taken together with the nitrogen to which they are attached from a heterocycle selected from morpholine, piperidine pyrrolidine and piperazine;

R.sup.15 is

(a) hydrogen,

(b) C.sub.1-5 alkyl,

(c) phenyl--C.sub.1-3 alkyl, wherein the phenyl is either unsubstituted or substituted with one or more of:

(1) hydroxy,

(2) C.sub.1-3 alkoxy,

(3) R.sup.17 R.sup.18 N--C.sub.1-3 alkyl;

(d) phenyl either unsubstituted or substituted with one or more of

(1) hydroxy,

(2) C.sub.1-3 alkoxy,

(3) R.sup.17 R.sup.18 N--C.sub.1-3 alkyl, or

(4) halo, such as chloro or fluoro

(e) aromatic heterocycle of 5 or 6 members selected from furyl, pyridyl, and thienyl either unsubstituted or substituted with R.sup.17 R.sup.18 N--C.sub.1-3 alkyl

(f) --NR.sup.17 R.sup.18, and

(g) C.sub.2-5 alkyl substituted with --NR.sup.17 R.sup.18 ;

R.sup.16 is

(a) hydrogen, or

(b) C.sub.1-3 alkyl;

with the proviso that if R.sup.14 is hydrogen, one of R.sup.15 and R.sup.16 is other than hydrogen, which comprises treating a compound of structural formula: ##STR29## with dimethyldichlorosilane and sodium iodide in an acetonitrile at about 75.degree. to 100.degree. C. for about one to 4 hours.

2. The process of claim 1 for preparing the compound of formula ##STR30##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Medtronic
Accenture
Fuji
Chinese Patent Office
Cantor Fitzgerald
AstraZeneca
Daiichi Sankyo
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot